IDWeek is the joint annual meeting of the Infectious Diseases Society of America, the Society for Healthcare Epidemiology of America, the HIV Medicine Association, the Pediatric Infectious Diseases Society and the Society of Infectious Diseases Pharmacists.
In advance of the confernece, The analyst highlighted highly
anticipated and noteworthy abstracts in this Pre-Conference Coverage report.Report Scope
Indications, companies, and therapies discussed in the report are as follows:
- Respiratory syncytial virus (RSV)
Moderna - mRNA-1345 (mRESVIA)
Enanta Pharmaceuticals - EDP-323- COVID-19
Moderna - mRNA-1273.815 (Spikevax XBB.1.5)
Invivyd - Pemivibart (Pemgarda)
- Complicated urinary tract infections (cUTIs)/acute pyelonephritis
GSK and Spero Therapeutics - Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr)
- HIV
ST Pharm - Pirmitegravir (STP0404)
- Nontuberculous mycobacteria (NTM)
Paratek Pharmaceuticals - Omadacycline (Nuzyra)
- Epstein Barr virus (EBV)
National Institute of Allergy and Infectious Diseases - EBV gp350 Ferritin Nanoparticle Vaccine Candidate adjuvanted with Matrix-M
- Complicated Staphylococcus aureus bacteremia (SAB)
- Fungal Infections
Reasons to Buy
- This powerpoint-based deliverable highlights noteworthy conference abstracts, and the potential implications for your strategy, covering disease areas such as HIV, COVID-19, RSV, NTM, UTIs, and more.
Table of Contents
1. Table of Contents2. Abbreviations
3. IDWeek 2025: Noteworthy Abstracts
4. Appendix
5. Contact the Publisher
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Moderna
- Enanta Pharmaceuticals
- Invivyd
- GSK
- Spero Therapeutics
- ST Pharm
- Paratek Pharmaceuticals
- National Institute of Allergy and Infectious Diseases
- Armata Pharmaceuticals
- Elion Therapeutics
